Open Accessibility Menu

Research & Education

Uncovering New Approaches to Cancer Treatment

Attracting outstanding scientists to expand and contribute to current research efforts is a primary goal of the Katzen Cancer Research Center. With state-of-the-art clinical facilities, the center is poised to considerably enhance its research efforts by adding scientists, clinicians and support staff dedicated to the discovery of new cancer therapies.

Each year, the Katzen Center provides the Innovative Pilot Cancer Research Grants Program, an intramural George Washington University research grants program awarding close to $500,000 annually. The grants explore uncharted territory in cancer research, with a goal of making significant improvements in cancer prevention, early diagnosis and treatment, and ultimately lead to a cure.

Clinical Trials

Katzen Center physicians conduct a wide variety of clinical trials in the areas of cancer treatment and research. A clinical trial is a research study to test how well investigational treatments work in patients. They are the safest and most effective way to examine a treatment for cancer. Participants in a clinical trial have access to up-to-date medical care from our Katzen Center physicians, new treatments and the best available standard of care for their type of cancer.

Areas of Research:

  • Breast cancer
  • Head & Neck cancer
  • Kidney cancer
  • Lung cancer
  • Lymphoma/Leukemia
  • Multiple Myeloma
  • Myelofibrosis
  • Myelodysplastic syndromes
  • Prostate cancer

For more information about specific grants and research, click here.

Education

With its affiliation to the GW School of Medicine and Health Sciences, the Katzen Cancer Research Center has access to physicians who wear multiple hats – as clinicians, researchers and educators. Committed to sharing the latest knowledge and evidence, these faculty members contribute to better cancer care through education. As the research activities of the center expand, educational activities will be designed to ensure that new developments are shared with the entire cancer research community.

Clinical Trials

  • Comparing Group Approaches to Improve Insomnia Symptoms Among Breast Cancer Survivors
    We are inviting women diagnosed with stage I-III breast cancer who have completed active treatment (e.g. surgery, chemotherapy, radiation) to participate in this research study. Through this study we will examine if our mind and body programs improve some of the long term effects of breast cancer treatment such as insomnia. This is a pilot phase of the study. This means that we are interested in feasibility of the program and will ask for your feedback about things you like and do not like about the program.
  • Combination immunotherapy with Herceptin and theHER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence
    This is a randomized trial for after all neo or adjuvant therapy is complete for women are Her2 1+ or HER2 2+
  • A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative early Breast Cancer (PALLAS Study)
    The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
  • A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
    This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized). Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed, and after nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.
  • A Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination with Letrozole for The Treatment of men and Pre/Postmenopausal Women With Hormone Receptor-Positive (HR+) HER-Negative (HER2-) Advanced Breast Cancer (aBC) with No Prior Hormonal Therapy for Advanced Disease
    The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
  • A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients-the INSIGHT-MM study
    The objective of this study is to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in patients with newly diagnosed multiple myeloma and patients with relapsed/refractory multiple myeloma.